New Age Alpha Advisors LLC Purchases Shares of 4,637 United Therapeutics Co. (NASDAQ:UTHR)

New Age Alpha Advisors LLC bought a new position in United Therapeutics Co. (NASDAQ:UTHR - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 4,637 shares of the biotechnology company's stock, valued at approximately $1,636,000.

Several other institutional investors also recently modified their holdings of the business. Norges Bank bought a new position in United Therapeutics during the fourth quarter valued at about $151,764,000. Mitsubishi UFJ Asset Management Co. Ltd. increased its stake in shares of United Therapeutics by 11.4% during the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 32,246 shares of the biotechnology company's stock worth $11,490,000 after purchasing an additional 3,312 shares during the last quarter. Korea Investment CORP raised its holdings in shares of United Therapeutics by 6.2% in the 4th quarter. Korea Investment CORP now owns 39,289 shares of the biotechnology company's stock worth $13,863,000 after purchasing an additional 2,300 shares during the period. Florida Financial Advisors LLC lifted its stake in United Therapeutics by 6.2% in the fourth quarter. Florida Financial Advisors LLC now owns 822 shares of the biotechnology company's stock valued at $290,000 after purchasing an additional 48 shares during the last quarter. Finally, Prudential Financial Inc. grew its holdings in United Therapeutics by 22.2% during the fourth quarter. Prudential Financial Inc. now owns 66,541 shares of the biotechnology company's stock valued at $23,478,000 after purchasing an additional 12,104 shares during the period. 94.08% of the stock is owned by institutional investors.

United Therapeutics Stock Performance

NASDAQ UTHR traded down $6.03 on Thursday, hitting $306.23. The stock had a trading volume of 232,712 shares, compared to its average volume of 449,393. The firm has a 50-day moving average of $336.64 and a 200-day moving average of $355.09. United Therapeutics Co. has a 52-week low of $227.75 and a 52-week high of $417.82. The company has a market capitalization of $13.75 billion, a price-to-earnings ratio of 13.45, a price-to-earnings-growth ratio of 0.97 and a beta of 0.64.

Remove Ads

United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its quarterly earnings results on Wednesday, February 26th. The biotechnology company reported $6.19 earnings per share for the quarter, topping the consensus estimate of $6.10 by $0.09. The firm had revenue of $735.90 million for the quarter, compared to analysts' expectations of $734.74 million. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. During the same quarter in the prior year, the firm posted $4.36 earnings per share. As a group, research analysts anticipate that United Therapeutics Co. will post 24.48 earnings per share for the current fiscal year.

Insider Buying and Selling at United Therapeutics

In other United Therapeutics news, Director Tommy G. Thompson sold 2,500 shares of United Therapeutics stock in a transaction that occurred on Monday, March 24th. The shares were sold at an average price of $318.80, for a total transaction of $797,000.00. Following the completion of the sale, the director now directly owns 8,480 shares in the company, valued at $2,703,424. The trade was a 22.77 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, COO Michael Benkowitz sold 10,000 shares of the business's stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $364.91, for a total transaction of $3,649,100.00. Following the completion of the transaction, the chief operating officer now directly owns 2,577 shares of the company's stock, valued at approximately $940,373.07. This represents a 79.51 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 72,500 shares of company stock valued at $26,134,500 in the last 90 days. Corporate insiders own 11.90% of the company's stock.

Wall Street Analysts Forecast Growth

UTHR has been the topic of several research reports. UBS Group boosted their target price on United Therapeutics from $415.00 to $475.00 and gave the company a "buy" rating in a research note on Wednesday, January 8th. HC Wainwright reaffirmed a "buy" rating and set a $425.00 price objective on shares of United Therapeutics in a report on Thursday, February 27th. Finally, StockNews.com lowered shares of United Therapeutics from a "strong-buy" rating to a "buy" rating in a research report on Thursday, February 27th. One analyst has rated the stock with a sell rating, two have issued a hold rating and ten have assigned a buy rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $388.25.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.